NCT04256707 2025-03-19
SPRINT
Karyopharm Therapeutics Inc
Phase 1/2 Completed
Clinical Trials
9 trialsNCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT02178436 2023-11-07
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT04854434 2023-11-03
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT01607905 2023-01-26
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT05093608 2022-10-17
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT02384850 2022-04-08
SENTINEL
GSO Global Clinical Research BV
Phase 1 Terminated
NCT02283359 2016-01-15
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT02137356 2015-09-03
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Sheba Medical Center
Phase 1 Unknown